


Pyrazofurin

| | | |
|---------------------------|--|----------------|
| Cat. No.: | HY-122502 | |
| CAS No.: | 30868-30-5 | |
| Molecular Formula: | C ₉ H ₁₃ N ₃ O ₆ | |
| Molecular Weight: | 259.22 | |
| Target: | DNA/RNA Synthesis | |
| Pathway: | Cell Cycle/DNA Damage | |
| Storage: | Powder | -20°C 3 years |
| | In solvent | -80°C 6 months |
| | | -20°C 1 month |



SOLVENT & SOLUBILITY

In Vitro

H₂O : 5 mg/mL (19.29 mM; ultrasonic and warming and heat to 60°C)

| Concentration | Mass | | |
|---------------|-----------|------------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 3.8577 mL | 19.2886 mL | 38.5773 mL |
| 5 mM | 0.7715 mL | 3.8577 mL | 7.7155 mL |
| 10 mM | 0.3858 mL | 1.9289 mL | 3.8577 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Pyrazofurin, a pyrimidine nucleoside analogue with antineoplastic activity, inhibits cell proliferation and DNA synthesis in cells by inhibiting uridine 5'-phosphate (UMP) synthase^[1]. Pyrazofurin is an active, sensitive orotate-phosphoribosyltransferase inhibitor with IC₅₀s between 0.06-0.37 μM in the three squamous cell carcinoma (SCC) cell lines Hep-2, HNSCC-14B and HNSCC-14C^[2].

REFERENCES

[1]. Ringer DP, et al. Alteration in de novo pyrimidine biosynthesis during uridine reversal of pyrazofurin-inhibited DNA synthesis. *Neuropsychopharmacology. J Biochem Toxicol.* 1991 Spring;6(1):19-27.

[2]. Peters GJ, et al. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines. *Nucleosides Nucleotides Nucleic Acids.* 2018;37(6):329-339.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA